ClinicalTrials.gg
Not yet recruitingNCT07365475AMASS2Updated Jan 26, 2026

Efficacy and Safety of Intra-Arterial Albumin as Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke

A Phase 2 interventional study of 20% human serum albumin in Acute Ischemic Stroke From Large Vessel Occlusion, sponsored by Tianjin Huanhu Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Tianjin Huanhu Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
306
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital — 10 open to participants now, 11 under way, 1 of them phase 3. Ischemic Stroke · Tianjin Huanhu Hospital.

Started
2026
the only one that year
Phase 2
2 of 12
2 open now
Primary completion
2028-06
later than 8 of 10 live
Registered
12th of 12
by date

Among the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, this one is the only one that started in 2026, is one of 2 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 12th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

10 of the 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Ischemic Stroke by Tianjin Huanhu Hospital, or all of them as a file.
02

Study summary

Stroke remains a predominant global public health challenge, ranking as the third leading cause of death and the fourth leading contributor to disability-adjusted life years (DALYs). According to the Global Burden of Disease Study 2021, there are approximately 93.8 million prevalent stroke cases and 11.9 million new cases worldwide. China bears one of the heaviest burdens, with over 2 million new cases annually. Acute ischemic stroke (AIS), caused by acute cerebrovascular occlusion, accounts for 80% of all strokes. Approximately 30% of AIS cases result from large vessel occlusion (LVO), which typically carries a poor prognosis due to the extensive area of infarction . Research indicates that early recanalization significantly improves clinical outcomes. Currently, intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are the standard treatments for achieving recanalization . For LVO-related AIS, MT has become the preferred clinical approach due to its extended therapeutic window and superior recanalization rates . However, despite successful recanalization in over 70% of patients, nearly 50% fail to achieve functional independence at 90 days, and mortality remains above 15% . Therefore, enhancing long-term functional outcomes in post-MT patients is a critical unmet clinical need. Human albumin is the most abundant protein in plasma. Beyond maintaining colloid osmotic pressure, it also possesses multiple biological effects, including anti-inflammatory, anti-platelet aggregation, antioxidant, and endothelial protective properties. We conducted a Phase I clinical trial (AMASS-1) for patients post-mechanical thrombectomy, administering human albumin via the internal carotid artery. The results showed that intra-arterial infusion of 20% human albumin at a dose of 0.60 g/kg was safe, with no significant differences in serious adverse reactions such as mortality [Albumin group (6.7%) vs Control group (6.7%), P > 0.05] and symptomatic intracranial hemorrhage [Albumin group (6.7%) vs Control group (13.3%), P > 0.05] compared to the control group. In summary, albumin adjunctive therapy demonstrates good safety and potential neuroprotective effects in patients after mechanical thrombectomy. To further systematically evaluate its efficacy and safety, we plan to conduct a Phase II clinical trial of mechanical thrombectomy combined with intra-arterial albumin infusion for acute ischemic stroke. This is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the efficacy and safety of intra-arterial infusion of 20% human serum albumin combined with mechanical thrombectomy versus mechanical thrombectomy alone in patients with acute ischemic stroke due to anterior circulation large vessel occlusion who have achieved recanalization after mechanical thrombectomy. A total of 306 patients are planned to be enrolled and randomly assigned in a 1:1 ratio using a dynamic minimization method to two groups: the Albumin Group (0.6 g/kg 20% human serum albumin plus Mechanical Thrombectomy) and the Control Group (Mechanical Thrombectomy alone). The primary efficacy objective of this study is to evaluate whether immediate intra-arterial infusion of 20% human albumin (0.6 g/kg) via the internal carotid artery following successful recanalization (eTICI ≥2b) improves clinical outcomes in patients with acute anterior circulation large vessel occlusion stroke, compared with mechanical thrombectomy alone. The study also aims to evaluate the safety and feasibility of immediate intra-arterial infusion of 20% human albumin (0.6 g/kg) via the internal carotid artery in patients with acute anterior circulation large vessel occlusion stroke who have achieved successful recanalization (eTICI ≥2b) following standard mechanical thrombectomy.

03

Conditions studied

  • Acute Ischemic Stroke From Large Vessel Occlusion

Browse trials for

Keywords

  • acute ischemic stroke
  • large vessel occlusion
  • mechanical thrombectomy
  • albumin
  • neuroprotection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Acute anterior circulation large vessel occlusion (including ICA/MCA-M1 tandem occlusion or isolated MCA-M1 occlusion) confirmed by CTA, MRA, or DSA, with successful recanalization (eTICI score ≥2b) confirmed by the final intraoperative DSA following mechanical thrombectomy
  • Baseline NIHSS scores ≥ 6
  • Non-contrast CT ASPECTS ≥6
  • Time from stroke onset (or last known well) to arterial puncture within 24 hours
  • Pre-stroke functional independence, defined as a modified Rankin Scale (mRS) score \<2
  • Written obtained from the patient or a legally authorized representative

Exclusion criteria

Exclusion Criteria:

  • Intracranial hemorrhage confirmed by cranial CT or MRI
  • Midline shift with significant mass effect on cranial CT or MRI
  • Isolated internal carotid artery (ICA) occlusion
  • History of heart failure or severe cardiovascular disease, including but not limited to pulmonary hypertension or pericardial effusion
  • Hemodynamically unstable arrhythmia (based on patient self-report or detected prior to infusion)
  • Symptoms or electrocardiographic evidence of acute myocardial infarction upon admission
  • Acute or chronic renal failure (serum creatinine >2.0 mg/dL
  • Severe anemia (hematocrit \<32%
  • Known to albumin or blood products
  • Pregnancy
  • Persistent hypertension (blood pressure ≥180/100mmHg) prior to albumin infusion
  • Current participation in other clinical trials
  • of less than 3 months
  • Concomitant severe pulmonary disease, such as , pulmonary fibrosis, pleural effusion, or acute respiratory distress syndrome
  • Any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
306 participants (estimated)

Study arms

  • Experimental
    Albumin Group

    Albumin Group Subjects assigned to the albumin treatment group after achieving successful recanalization (eTICI ≥ 2b) confirmed by DSA post-thrombectomy will receive a 20% human albumin solution at a dose of 0.60 g/kg. The solution will be administered as a constant-rate infusion into the proximal internal carotid artery over 20 minutes. Vital signs and potential infusion-related reactions must be closely monitored throughout the procedure. Mechanical thrombectomy must be performed using clinically approved devices. The specific technical approach is to be determined by the neurointerventional physician based on the patient's individual clinical condition.

    Drug: 20% human serum albumin

  • No intervention
    Control Group

    Subjects in the control group who have achieved successful recanalization (eTICI ≥ 2b) as confirmed by DSA following mechanical thrombectomy will not receive the investigational infusion and will undergo standard medical management only. The mechanical thrombectomy procedure must be performed using clinically approved devices. The specific technical approach is to be determined at the discretion of the neurointerventional physician based on the patient's clinical condition.

Interventions

  • DrugAlbumins humanStudies of Albumins humanAlbumins human pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    20% human albumin solution at a dose of 0.60g/kg will be administered as a constant-rate infusion into the proximal internal carotid artery over 20 minutes.

06

What researchers measure

Primary outcomes

  1. Distribution of mRS scores at 90 (±14) days post-randomization

    Distribution of mRS scores

    Time frame: at 90 (±14) days post-randomization

Secondary outcomes

  1. Proportion of subjects with a favorable outcome at 90 (±14) days post-randomization (defined as mRS 0-2);

    Proportion of subjects with a favorable outcome, defined as mRS 0-2

    Time frame: at 90 (±14) days post-randomization

  2. Proportion of subjects with functional independence at 90 (±14) days post-randomization (defined as mRS 0-1)

    Proportion of subjects with functional independence, defined as mRS 0-1

    Time frame: at 90 (±14) days post-randomization

  3. Infarct volume at 24 (±6) hours post-randomization (measured via MRI-DWI)

    Infarct volume, measured via MRI-DWI

    Time frame: at 24 (±6) hours post-randomization

  4. Infarct volume growth from baseline to 24 (±6) hours post-randomization

    Infarct volume growth

    Time frame: from baseline to 24 (±6) hours post-randomization

  5. Recanalization rate at 24 (±6) hours post-randomization

    Recanalization rate

    Time frame: at 24 (±6) hours post-randomization

  6. NIHSS score at 24 (±6) hours post-randomization

    NIHSS score

    Time frame: at 24 (±6) hours post-randomization

  7. NIHSS score at 7 (±1) days or at discharge, whichever occurs first

    NIHSS score

    Time frame: at 7 (±1) days or at discharge, whichever occurs first

  8. EQ-5D-5L score at 90 (±14) days post-randomization

    EQ-5D-5L score

    Time frame: at 90 (±14) days post-randomization

  9. Proportion of subjects with a Barthel Index (BI) ≥95 at 90 (±14) days post-randomization

    Proportion of subjects with a Barthel Index (BI)

    Time frame: at 90 (±14) days post-randomization

  10. Distribution of mRS scores at 180 (±30) days and 1 year (±30 days) post-randomization

    Distribution of mRS scores

    Time frame: at 180 (±30) days and 1 year (±30 days) post-randomization

  11. Proportion of subjects with a favorable outcome (mRS 0-2) at 180 (±30) days and 1 year (±30 days) post-randomization

    Proportion of subjects with a favorable outcome (mRS 0-2)

    Time frame: at 180 (±30) days and 1 year (±30 days) post-randomization

  12. EQ-5D-5L score at 180 (±30) days and 1 year (±30 days) post-randomization

    EQ-5D-5L score

    Time frame: at 180 (±30) days and 1 year (±30 days) post-randomization

  13. Proportion of subjects with a Barthel Index (BI) ≥95 at 180 (±30) days and 1 year (±30 days) post-randomization

    Proportion of subjects with a Barthel Index (BI) ≥95

    Time frame: at 180 (±30) days and 1 year (±30 days) post-randomization

  14. All-cause mortality within 90 (±14) days post-randomization

    All-cause mortality

    Time frame: within 90 (±14) days post-randomization

  15. Symptomatic intracranial hemorrhage (sICH) at 24 (±6) hours post-randomization (according to ECASS III criteria)

    Symptomatic intracranial hemorrhage (sICH) ,according to ECASS III criteria

    Time frame: at 24 (±6) hours post-randomization

  16. Serious adverse events (SAEs) within 90 (±14) days post-randomization

    SAEs

    Time frame: within 90 (±14) days post-randomization

  17. Adverse events (AEs) within 90 (±14) days post-randomization

    AEs

    Time frame: within 90 (±14) days post-randomization

  18. Early neurological deterioration (END), defined as an increase in NIHSS score of ≥4 points from baseline at 24 hours post-randomization

    END, defined as an increase in NIHSS score of ≥4 points from baseline at 24 hours post-randomization

    Time frame: from baseline at 24 hours post-randomization

  19. Proportion of subjects with severe disability at 90 (±14) days post-randomization (defined as mRS 4-6)

    Proportion of subjects with severe disability , defined as mRS 4-6

    Time frame: at 90 (±14) days post-randomization

  20. Albumin-related adverse events within 90 (±14) days post-randomization

    Albumin-related adverse events

    Time frame: within 90 (±14) days post-randomization

  21. SAEs and AEs within 180 (±30) days post-randomization

    SAEs and AEs

    Time frame: within 180 (±30) days post-randomization

  22. SAEs and AEs within 1 year (±30 days) post-randomization

    SAEs and AEs

    Time frame: within 1 year (±30 days) post-randomization

Other outcomes

  1. Levels of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the blood at 24 (±6) hours post-randomization

    Levels of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the blood

    Time frame: at 24 (±6) hours post-randomization

  2. Serum albumin and B-type natriuretic peptide (BNP) levels at 24 (±6) hours post-randomization

    Serum albumin and B-type natriuretic peptide (BNP) levels

    Time frame: at 24 (±6) hours post-randomization

  3. Levels of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the blood at 7 (±1) days post-randomization or at discharge (whichever occurs first)

    Levels of inflammatory cytokines (IL-1β, TNF-α, IL-6, IL-10) in the blood

    Time frame: at 7 (±1) days post-randomization or at discharge (whichever occurs first)

  4. Serum albumin and BNP levels at 7 (±1) days post-randomization or at dis charge (whichever occurs first)

    Serum albumin and BNP levels

    Time frame: at 7 (±1) days post-randomization or at dis charge (whichever occurs first)

  5. Net water uptake (NWU) at 24 (±6) hours post-randomization

    Net water uptake (NWU)

    Time frame: at 24 (±6) hours post-randomization

  6. Progression of net water uptake from baseline to 24 (±6) hours post-randomization

    Progression of net water uptake

    Time frame: from baseline to 24 (±6) hours post-randomization

  7. Cerebrospinal fluid (CSF) volume at 24 (±6) hours post-randomization

    Cerebrospinal fluid (CSF) volume

    Time frame: at 24 (±6) hours post-randomization

  8. Change in cerebrospinal fluid volume from baseline to 24 (±6) hours post-randomization

    Change in cerebrospinal fluid volume

    Time frame: from baseline to 24 (±6) hours post-randomization

  9. Analysis of the Index for Connectivity via Perivascular Spaces (ALPS index) at 24 (±6) hours post-randomization

    Analysis of the Index for Connectivity via Perivascular Spaces (ALPS index)

    Time frame: at 24 (±6) hours post-randomization

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jun 2028, 29 months later.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 29 months is close to that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2026
First posted
Jan 26, 2026
StartEst.
Jan 30, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Aug 30, 2028
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07365475
Lead sponsor
Tianjin Huanhu Hospital
Responsible party
Ming Wei (PhD, Tianjin Huanhu Hospital) — Principal investigator
First posted
Jan 26, 2026
Start date
Jan 30, 2026 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Aug 30, 2028 (estimated)
Last update
Jan 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Albumins human

Start the discussion